Improving risk assessment of local failure in brain metastases patients using vision transformers - A multicentric development and validation study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published Date:

Abstract

BACKGROUND AND PURPOSE: This study investigates the use of Vision Transformers (ViTs) to predict Freedom from Local Failure (FFLF) in patients with brain metastases using pre-operative MRI scans. The goal is to develop a model that enhances risk stratification and informs personalized treatment strategies.

Authors

  • Ayhan Can Erdur
    Institute for Artificial Intelligence and Informatics in Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str., 81675, Munich, Bavaria, Germany. can.erdur@tum.de.
  • Daniel Scholz
    Institute for Artificial Intelligence and Informatics in Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str., 81675, Munich, Bavaria, Germany.
  • Q Mai Nguyen
    Department of Radiation Oncology, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Josef A Buchner
    Department of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str., 81675, Munich, Bavaria, Germany.
  • Michael Mayinger
    Department of Radiation Oncology, University of Zurich, Zurich, Switzerland.
  • Sebastian M Christ
    Department of Radiation Oncology, University of Zurich, Zurich, Switzerland.
  • Thomas B Brunner
    Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany.
  • Andrea Wittig
    University Hospital Würzburg, Department of Radiotherapy and Radiation Oncology, Josef-Schneider-Str. 11, 97080 Würzburg, Germany.
  • Claus Zimmer
    Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany.
  • Bernhard Meyer
    Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany.
  • Matthias Guckenberger
    Department of Radiation Oncology, University Hospital Zurich, Switzerland.
  • Nicolaus Andratschke
    Department of Radiation Oncology, University Medicine Rostock, Rostock, Germany. nicolaus.andratschke@usz.ch.
  • Rami A El Shafie
    Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute for Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg, Germany; Department of Radiation Oncology, University Medical Center G¨ottingen, Göttingen, Germany.
  • J Urgen Debus
    Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute for Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg, Germany.
  • Susanne Rogers
    Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland.
  • Oliver Riesterer
    University Hospital Zurich and University of Zurich, Department of Radiation Oncology, Zurich, Switzerland.
  • Katrin Schulze
    Department of Radiation Oncology, General Hospital Fulda, Fulda, Germany.
  • Horst J Feldmann
    Department of Radiation Oncology, General Hospital Fulda, Fulda, Germany.
  • Oliver Blanck
  • Constantinos Zamboglou
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany constantinos.zamboglou@uniklinik-freiburg.de.
  • Angelika Bilger-Z
    Department of Radiation Oncology, University of Freiburg - Medical Center, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
  • Anca L Grosu
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
  • Robert Wolff
  • Kerstin A Eitz
    Department of Radiation Oncology, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Deutches Konsortium f¨ur Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Helmholtz Center Munich, Munich, Germany.
  • Stephanie E Combs
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675 Munich, Germany; Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.
  • Denise Bernhardt
    Department of Radiation Oncology, School of Medicine and Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Benedikt Wiestler
    Department of Neuroradiology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675 Munich, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.
  • Daniel Rueckert
    Biomedical Image Analysis (BioMedIA) Group, Department of Computing, Imperial College London, UK. Electronic address: d.rueckert@imperial.ac.uk.
  • Jan C Peeken
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675 Munich, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.

Keywords

No keywords available for this article.